Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 2/20 | 0.43 |
| ▸ | ADH1C | P00326 | 2/20 | 0.43 |
| ▸ | ADH1A | P07327 | 2/20 | 0.43 |
| ▸ | ADH4 | P08319 | 2/20 | 0.43 |
| ▸ | ADH7 | P40394 | 1/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.34 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5542802 | 1.00 | ADH1B (0.43) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL72483 | 1.00 | ADH1B (0.43) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL28331883 | 1.00 | ADH1B (0.43) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL457302 | 0.97 | — | — | |
| SCHEMBL317021 | 0.92 | — | — | |
| Hydrochloric Acid SCHEMBL28855937 | 0.90 | ADH1B (0.38) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL17102571 | 0.88 | ADH1B (0.35) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL30435158 | 0.87 | SLC1A3 (0.34) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL133081 | 0.87 | — | — | |
| SCHEMBL4773943 | 0.82 | ADH1B (0.38) | ADH1BADH1CADH1AADH4ADH7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-0567271-A2 | Steroid derivatives for the treatment of prostatic hypertrophy, their preparation and uses | SANKYO COMPANY LIMITED (JP) | 1993-10-27 | — | — | EP | disclosed |
| EP-0275381-B1 | DYE TRANSFER PROCESS | BASF Aktiengesellschaft (DE) | 1992-03-04 | — | — | EP | disclosed |
| EP-0275381-A2 | Dye transfer process | BASF Aktiengesellschaft (DE) | 1988-07-27 | — | — | EP | disclosed |
| US-4760049-A | Dye transfer | BASF AKTIENGESELLSCHAFT (DE) | 1988-07-26 | — | — | US | disclosed |
| US-4604460-A | ANTIBIOTICS, BACTERICIDES | SHIONOGI & CO., LTD. (JP) | 1986-08-05 | — | — | US | disclosed |
| US-4533730-A | BACTERICIDES | SHIONOGI & CO., LTD. (JP) | 1985-08-06 | — | — | US | disclosed |
| US-4504659-A | 1-Oxadethiacepham compounds | SHIONOGI & CO., LTD. (JP) | 1985-03-12 | — | — | US | disclosed |
| US-4478997-A | 1-Oxadethiacepham compounds | SHIONOGI & CO., LTD. (JP) | 1984-10-23 | — | — | US | disclosed |
| US-4443598-A | ANTIBIOTICS AND INTERMEDIATES | SHIONOGI & CO., LTD. (JP) | 1984-04-17 | — | — | US | disclosed |
| US-4366316-A | FROM OXAZOLINOAZETIDINONE AND ACID | SHIONOGI & CO., LTD. (JP) | 1982-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | ADH1B 281/4885ADH1C 285/4885ADH1A 494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.